A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

November 13, 2024

Study Completion Date

November 13, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

AK120

subcutaneous injection every 2 weeks

Trial Locations (26)

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

Air Force Medical Center, Beijing

China-Japan Friendship Hospital, Beijing

Peking University Third Hospital, Beijing

The Second Affiliated Hospital of Xiamen Medical College, Xiamen

Dongguan People's Hospital, Dongguan

Dermatology Hospital of Southern Medical University, Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

Shenzhen People's Hospital, Shenzhen

The Second Hospital of Hebei Medical University, Shijiazhuang

People Hospital of Xingtai, Xingtai

Renmin Hospital of Wuhan University Hubei General Hospital, Wuhan

Affiliated Hospital of Nantong University, Nantong

Yancheng No.1 People's Hospital, Yancheng

The Second Affiliated Hospital of Nanchang University, Nanchang

General Hospital of Ningxia Medical University, Yinchuan

Qingdao Municipal Hospital, Qingdao

Baoji Central Hospital, Baoji

Second Hospital of Shanxi Medical University, Taiyuan

Taiyuan Central Hospital, Taiyuan

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin

The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou

Ningbo No.2 Hospital, Ningbo

The first affiliated Hospital of Wenzhou Medical University, Wenzhou

The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akeso

INDUSTRY